RxDoctor Payments Data

Valerie Jakubos, APRN

Adult Health · Reno, NVNPI 1538780424

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.

$1,197in general payments, 2019–2025

Across 54 payments — averaging $22.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$283
  • Edwards Lifesciences$249
  • Pfizer$120
  • Actelion Pharmaceuticals US, Inc.$116
  • Novartis$107
  • Bayer$82
  • plus $240 from 8 others

What the payments were for

  • Food & beverage$1,197100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,197 in reported general payments places this provider in the 60th percentile of 90 adult health providers in Nevada.

See all adult health providers in Nevada

Medicare billing

Part B allowed, 2024
$55,777
Medicare patients
467
Services billed
707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$167,339
XareltoRivaroxaban33$44,456
EntrestoSacubitril/Valsartan12$13,218
Praluent PenAlirocumab15$11,439
BrilintaTicagrelor13$7,244
Atorvastatin Calcium180$3,057
Metoprolol Succinate155$1,954
Prasugrel Hcl20$1,344
Rosuvastatin Calcium82$1,251
Losartan Potassium108$1,068
Ezetimibe33$956
Amlodipine Besylate130$943
Potassium Chloride47$799
Carvedilol76$699
ClopidogrelClopidogrel Bisulfate65$653

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$120$167,339178 claims
Johnson & JohnsonXarelto$51$44,45633 claims
NovartisEntresto$107$13,21812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 90 adult health providers in Nevada.

Other adult health in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →